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Background: The aim of the present work was to assess the in vitro cross-resistance of pyronaridine with other
quinoline drugs, artesunate and several other commonly used anti-malarials and to evaluate whether decreased
susceptibility to pyronaridine could be associated with genetic polymorphisms in genes involved in reduced
quinoline susceptibility, such as pfcrt, pfmdr1, pfmrp and pfnhe.
Methods: The in vitro chemosusceptibility profiles of 23 strains of Plasmodium falciparum were analysed by the
standard 42-hour
3H-hypoxanthine uptake inhibition method for pyronaridine, artesunate, chloroquine,
monodesethylamodiaquine, quinine, mefloquine, lumefantrine, atovaquone, pyrimethamine and doxycycline.
Genotypes were assessed for pfcrt, pfmdr1, pfnhe-1 and pfmrp genes.
Results: The IC50 values for pyronaridine ranged from 15 to 49 nM (geometric mean = 23.1 nM). A significant
positive correlation was found between responses to pyronaridine and responses to artesunate (r
2 = 0.20; P =
0.0317) but too low to suggest cross-resistance. No significant correlation was found between pyronaridine IC50
and responses to other anti-malarials. Significant associations were not found between pyronaridine IC50 and
polymorphisms in pfcrt, pfmdr1, pfmrp or pfnhe-1.
Conclusion: There was an absence of cross-resistance between pyronaridine and quinolines, and the IC50 values
for pyronaridine were found to be unrelated to mutations in the transport protein genes pfcrt, pfmdr1, pfmrp or
pfnhe-1, known to be involved in quinoline resistance. These results confirm the interest and the efficacy of the use
of a combination of pyronaridine and artesunate in areas in which parasites are resistant to quinolines.
Background
Over the past 20 years, many strains of Plasmodium falci-
parum have become resistant to chloroquine and other
anti-malarial drugs [1]. This development has prompted a
search for new effective anti-malarial drugs with minimal
side effects. One strategy for reducing the prevalence of
malaria is the use of drug combinations, which is thought
to protect each drug from the development of resistance
and reduce the overall transmission of malaria [2]. Since
2001, more than 60 countries have officially adopted arte-
misinin-based combination therapy (ACT) for the treat-
ment of falciparum malaria [3,4]. The artemisinin
derivatives cause a rapid and effective reduction in parasite
biomass as well as gametocyte carriage, while the partner
drug, which has a longer duration of action, achieves effec-
tive clinical and parasitological cure. Several different
forms of ACT have been evaluated, including artesunate-
sulphadoxine-pyrimethamine [5], artesunate-amodiaquine
[6], artemether-lumefantrine [7], artesunate-mefloquine
[8], artesunate-chloroproguanil-dapsone [9], artesunate-
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[10] and artesunate-pyronaridine [11].
However, clinical failures or at least longer parasite
clearance times have been described in Cambodia
[12-15]. In addition, prior therapy with an amodiaquine-
containing ACT has been found to select for a reduced
response to monodesethylamodiaquine, suggesting that
amodiaquine-containing regimens may rapidly lose effi-
cacy in Africa [16]. This emergence of parasite resis-
tance to some forms of ACT indicates that novel
compounds and combinations must be discovered and
developed.
A pyronaridine-artesunate combination (Pyramax®) is
one of the latest ACT combinations currently under
development by the not-for-profit organization Medi-
cines for Malaria Venture (Geneva, Switzerland) and the
pharmaceutical company Shin Poong Pharmaceuticals
(Seoul, Republic of Korea) for the treatment of uncom-
plicated P. falciparum malaria and for the blood stages
of Plasmodium vivax malaria. Pyramax® has recently
completed phase III trials in humans.
Pyronaridine, a Mannich base, has been shown to be
highly effective against P. falciparum and P. vivax,w i t h
few side effects in clinical trials involving more than
1,000 Chinese patients [17]. Pyronaridine is also effective
in children in cases that are resistant to chloroquine
[18]. However, there are insufficient preclinical pharma-
cology data on this combination therapy, and little infor-
mation exists regarding the mechanisms of action as
well as interactions between the two components in
terms of anti-malarial activity. Furthermore, there are
no reports on the influence of known resistance
mechanisms on parasite susceptibility. While antagon-
ism in vitro has been reported for combinations of pyro-
naridine and dihydroartemisinin or artesunate [19,20],
the same combinations demonstrated in vivo synergy in
a rodent model [20].
The aims of the present work were as follows: i) to
assess the in vitro cross-resistance of pyronaridine with
other quinoline drugs, including chloroquine, quinine,
mefloquine, monodesethylamodiaquine, lumefantrine,
and artesunate, atovaquone, pyrimethamine and doxycy-
cline; and ii) to identify genetic polymorphisms that
could be associated with decreased susceptibility to pyr-
onaridine in the genes pfcrt, pfmrp, pfmdr1 and pfnhe-1,
which are known to be associated with reduced quino-
line susceptibility [21-24], with the goal of identifying




A total of 23 pre-identified parasite strains (well-charac-
terized laboratory strains or strains obtained from
isolates after growth in culture for an extended
period of time) from a wide panel of countries (Brazil,
Cambodia, Cameroon, Comoros, Djibouti, the Gambia,
French Guyana, Honduras, Niger, Republic of Congo,
Senegal, Sierra Leone, Sudan, Thailand and Uganda)
were maintained in culture in RPMI 1640 (Invitrogen,
Paisley, United Kingdom), supplemented with 10%
human serum (Abcys S.A. Paris, France) and buffered
with 25 mM HEPES and 25 mM NaHCO3. Parasites
w e r eg r o w ni nt y p eA
+ human red blood cells under
controlled atmospheric conditions that consisted of 10%
O2,5 %C O 2 and 85% N2 at 37°C with a humidity of
95%. All strains were synchronized twice with sorbitol
before use [25]. Clonality was verified using PCR geno-
typing of polymorphic genetic markers msp1, msp2,a n d
microsatellite loci [26,27]. The susceptibility of each
strain to anti-malarial drugs was assessed in 6 to 21
independent experiments.
Drugs
Pyronaridine and artesunatew e r eo b t a i n e df r o mS h i n
Poong Pharm Co. (Seoul, Korea). Chloroquine, quinine,
pyrimethamine and doxycycline were purchased from
Sigma (Saint Louis, MO). Monodesethylamodiaquine
was obtained from the World Health Organisation
(Geneva, Switzerland). Mefloquine was from Roche
(Paris, France), lumefantrine was from Novartis Pharma
(Basel, Switzerland) and atovaquone was from GlaxoS-
mithKline (Evreux, France). Pyronaridine, chloroquine
and pyrimethamine were dissolved and diluted in water
in concentrations ranging from 0.15 to 100 nM for pyr-
onaridine, 5 to 3200 nM for chloroquine and 5 to 40000
nM for pyrimethamine. Quinine, monodesethylamodia-
quine, mefloquine, artesunate, atovaquone and doxycy-
cline were dissolved first in methanol and then diluted
in water to obtain final concentrations ranging from 5
to 3200 nM for quinine, 1.56 to 1000 nM for monode-
sethylamodiaquine, 3.2 to 400 nM for mefloquine, 0.1 to
100 nM for artesunate, 0.3 to 100 nM for atovaquone and
0.1 to 502 μM for doxycycline. Lumefantrine was resus-
pended and diluted in ethanol to obtain final concentrations
ranging from 0.5 to 310 nM. Each drug concentration was
tested in triplicate in each individual assay.
In vitro assay
For in vitro isotopic microtests, 200 μL/well of a suspen-
sion of synchronous parasitized red blood cells (final
parasitaemia, 0.5%; final haematocrit, 1.5%) was distribu-
ted in 96-well plates predosed with anti-malarial drugs.
Parasite growth was assessed by adding 1 μCi of tritiated
hypoxanthine with a specific activity of 14.1 Ci/mmol
(Perkin-Elmer, Courtaboeuf, France) to each well at
time zero. The plates were then incubated for 48 h in
controlled atmospheric conditions. Immediately after
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erythrocytes. The contents of each well were collected
on standard filter microplates (Unifilter GF/B; Perkin-
Elmer) and washed using a cell harvester (Filter-Mate
Cell Harvester; Perkin-Elmer). The filter microplates
were dried, and 25 μL of scintillation cocktail (Micro-
scint O; Perkin-Elmer) was placed in each well. The
radioactivity incorporated in nucleotides by the parasites
was measured with a scintillation counter (Top Count;
Perkin-Elmer).
The drug concentration able to inhibit 50% of parasite
growth (IC50) was designated as the concentration at
which the tritiated hypoxanthine incorporation reached
50% of the total incorporation by parasites in the drug-
free control wells. The IC50 value was determined by
non-linear regression analysis of log-based dose-
response curves (Riasmart, Packard, Meriden, USA).
Nucleic acid extraction
Total genomic DNA of each strain was isolated using
the E.Z.N.A. Blood DNA kit (Omega Bio-Tek, GA, U.S.
A.) extraction method. RNA from each strain was puri-
fied using the QIAamp Blood Mini kit (QIAGEN,
Germany).
pfcrt single nucleotide polymorphisms (SNPs)
A 1250-nucleotide length fragment of the pfcrt gene was
amplified by RT-PCR using F1-sense 5’-TAA TTT CTT
ACA TAT AAC AAA ATG AAA TTC-3’ and F1-anti-
sense 5’-TTA TTG TGT AAT AAT TGA ATC GAC-3’
primers and sequenced using F2-sense 5’-TAG GTG
GAG GTT CTT GTC TTG GTA-3’ and F2-antisense
5’-TCG ACG TTG GTT AAT TCT CCT TC-3’ primers
as previously described [28]. Amplifications were per-
formed using the Access RT-PCR System kit (Promega,
WI, U.S.A.) according to the manufacturer’si n s t r u c -
tions. Sequencing was conducted using ABI Prism Big
Dye Terminator v1.1 (Applied Biosystems, CA, U.S.A)
cycle sequencing ready reaction kits according to the
manufacturer’s instructions.
pfmdr1 SNPs
pfmdr1 (PFE1150w) was amplified by PCR using the fol-
lowing primer pairs 5’-AGA GAA AAA AGA TGG
TAA CCT CAG-3’ and 5’-ACC ACA AAC ATA AAT
TAA CGG-3’ to amplify codons 86 and 184 and 5’-CAG
GAA GCA TTT TAT AAT ATG CAT-3’ and 5’-CGT
TTA ACA TCT TCC AAT GTT GCA-3’ to amplify
codons 1034, 1042, and 1246. The reaction mixture con-
sisted of approximately 200 ng of genomic DNA,
0.5 μM of forward and reverse primers, buffer (50 mM
KCl, 10 mM Tris, pH 8.3), 2.5 mM MgCl2, 200 μM
deoxynucleotide triphosphate (dNTP) and 0.3 U Taq
DNA polymerase (Eurogentec) in a final volume of
50 μL. The thermal cycler (T3 Biometra) was pro-
grammed as follows: an initial 94°C for 2 min followed
by 40 cycles of 94°C for 30 sec, 52°C for 30 sec and 72°
C for 1 min. A final 15-min extension step was done at
72°C. The amplified fragments were sequenced as pre-
viously described. Sequences were analysed with the
software BioEdit Sequence Alignment Editor 7.0.9.0.
pfmrp SNPs
PCR amplification followed by sequencing was used to
detect SNPs in pfmrp at positions 191 and 437. The
primers used for amplification and sequencing were
pfmrp-501F 5’-TTT CAA AGT ATT CAG TGG GT-3’
and pfmrp-1409R 5’-GGC ATA ATA ATT GAT GTA
AA-3’.
pfnhe-1 microsatellite profiles
A sequence containing the previously described ms4760
microsatellite was amplified using pfnhe-3802F
5’-TTATTAAATGAATATAAAGA-3’ and pfnhe-4322R
5’-TTTTTTATCATTACTAAAGA-3’ primers [29]. The
amplified fragments were sequenced as previously
described.
Statistical analysis
Assessment of cross-resistance of standard anti-malarial
drugs with pyronaridine was estimated by coefficient of
correlation (r) and coefficient of determination (r
2). The
Kruskal-Wallis test or Mann-Whitney U test was used,
when appropriate, to compare the IC50 values for each
gene mutation.. The differences in IC50 for pyronaridine
were then tested 19 times (i.e., once per locus). The prob-
ability of getting a significant result with 19 tests at the a
= 0.05 level of significance was 1-0.95
19 (1-probability of
not getting a significant result with 19 tests). According
to the Bonferroni correction, it was concluded that a dif-
ference was significant when at least one of the 19 com-
parisons yielded a significance level below 0.05/19 =
0.0026.
Results
Twenty-three P. falciparum strains were tested for their
in vitro susceptibility to pyronaridine, artesunate, chlor-
oquine, quinine, mefloquine, monodesethylamodiaquine,
lumefantine, atovaquone, pyrimethamine and doxycy-
cline (Additional file 1 and Additional file 2). The mean
IC50 values for pyronaridine are shown in Additional file
1. The IC50 values for pyronaridine ranged from 15 to
49 nM (geometric mean = 23.1 nM, 95% CI 20-26 nM).
In vitro cross-resistance was measured by pairwise
correlation of IC50 values of all 23 strains (Table 1 and
Additional file 3). A significant positive correlation was
found between responses to pyronaridine and responses
to artesunate (r
2 = 0.20; P = 0.0317). These coefficients
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oquine and monodesethylamodiaquine (r
2 = 0.84; P <
0.0001), chloroquine and quinine (r
2 =0 . 7 8 ;P < 0.0001)
or monodesethylamodiaquine and quinine (r
2 =0 . 7 2 ;
P < 0.0001). No significant correlation was found
between pyronaridine IC50 and responses to other anti-
malarial drugs, with the exception of artesunate.
The following amino acid substitutions were identified
for at least one strain: pfcrt M74I, N75E, K76T, A220 S,
Q271 (E/V), N326 S, I356T and I371R; pfmrp H191Y
and S437A; and pfmdr1 N86Y, Y184F, S1034C, N1042
D and D1246Y (Additional file 1). Eight different
ms4760 microsatellite profiles of pfnhe-1 were observed.
The number of DNNND and DDNHNDNHNN repeats
in ms4760 ranged from 1 to 4 and 1 to 3, respectively.
No significant association was found between pyronar-
idine IC50 (0.0556 <P < 0.8248) and polymorphism in
pfcrt, pfmdr1, pfmrp or pfnhe-1. However, significant
associations were found between responses to chloro-
quine, monodesethylamodiaquine, quinine and meflo-
quine and polymorphism in pfcrt, as well as between
responses to monodesethylamodiaquine and quinine and
polymorphism in pfmrp (Additional file 4). The associa-
tions between ms4760 profiles, number of DNNND
repeats and quinine, chloroquine, monodesethylamodia-
quine or mefloquine responses were not significant
according to the Bonferroni correction (P <0 . 0 5b u t>
0.0026). In addition, polymorphism in pfmdr1 (codons
1034 and 1042) and quinine or mefloquine responses
were not significantly associated according to the Bon-
ferroni correction (P < 0.05 but > 0.0026).
Discussion
The continued spread of P. falciparum drug resistance
to monotherapies has forced a shift toward the use of
ACT. Nevertheless, resistance to at least one component
of some forms of ACT currently in clinical use has been
documented, and it is feared that ACT will gradually
lose its clinical efficacy due to widespread use. Indivi-
dual P. falciparum parasites with longer clearance times
have been described in Cambodia [12-15]. In addition,
prior therapy with an amodiaquine-containing ACT has
been found to select for a reduced response to monode-
sethylamodiaquine, suggesting that amodiaquine-
containing regimens may rapidly lose efficacy in Africa
[16]. Antagonistic in vitro drug interactions between
pyronaridine and artemisinin derivatives have been
described [19,20,30]. In addition, previous studies have
demonstrated in vitro cross-resistance between pyronari-
dine and dihydroartemisinin or chloroquine, with coeffi-
cients of determination of 0.84 and 0.19-0.46,
respectively [31-35]. However, the combination of pyro-
naridine and artesunate has undergone successful clini-
cal evaluation in Africa [11]. The goal of the present
study was to investigate the susceptibility of several
strains of P. falciparum to pyronaridine, artesunate and
the commonly used antimalarial drugs, as well as to
determine cross-susceptibilities between these drugs and
the molecular determinants of susceptibility.
Twenty-three P. falciparum strains were tested for
their in vitro susceptibility to pyronaridine, artesunate,
chloroquine, quinine, mefloquine, monodesethyamodia-
quine, lumefantrine, atovaquone, pyrimethamine and
doxycycline. The IC50 values for pyronaridine ranged
from 15 to 49 nM (geometric mean = 23.1 nM, 95% CI
20-26 nM). These values are in accordance with pre-
vious studies on P. falciparum strains (1.9 to 47.8 nM)
[32] or in isolates of Thailand from patients cured with
pyronaridine (geometric mean = 15.7 nM) or that recru-
desced after pyronaridine treatment (geometric mean =
23.0 nM) [33] but higher than those found in isolates
from Cameroon (geometric mean = 3.58 nM), Senegal
(geometric mean = 3.8 nM and 4.52 nM) and Gabon
(geometric mean = 3.0 nM and 1.87 nM) [19,31,34-36].
However, pyronaridine was found to be highly active
against chloroquine- and pyrimethamine-resistant
strains and against parasites with reduced susceptibility
to quinine, monodesethylamodiaquine or mefloquine.
Encouragingly, no correlation was found between pyr-
onaridine and the other quinoline drugs (i.e., chloro-
quine, quinine, monodesethylamodiaquine, lumefantrine
or mefloquine). However, there have been conflicting
reports on the correlations between P. falciparum
responses to pyronaridine and chloroquine. Previous
studies showed weak (from 0.13 to 0.26) [31,34,35] to
middle (0.40 and 0.46) [32,33] coefficients of determina-
tion for correlations between pyronaridine and chloro-
quine. Pyronaridine appeared to be equally effective in
vitro against 37 isolates from two areas of Thailand with
different chloroquine resistance levels [37]. Similarly,
Table 1 Correlation of in vitro responses of 23 strains of
Plasmodium falciparum to pyronaridine (PND), and
artesunate (AS), chloroquine (CQ), quinine (QN),
mefloquine (MQ), monodesethylamodiaquine (MDAQ),
lumefantrine (LMF), atovaquone (ATV), pyrimethamine
(PY) and doxycycline (DOX)
Drug pair r r
2 P-value
PND AS + 0.4488 0.2014 0.0317
PND ATV + 0.3758 0.1412 0.0772
PND PY + 0.2116 0.0448 0.3323
PND QN + 0.2035 0.0414 0.3516
PND MQ - 0.3124 0.1050 0.1468
PND DOX - 0.1782 0.0318 0.4159
PND LMF - 0.1412 0.0199 0.5205
PND MDAQ - 0.1050 0.0110 0.6335
PND CQ - 0.0548 0.0030 0.8040
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tance to pyronaridine and chloroquine for 31 isolates
from Central and West Africa [38]. These results sug-
gest that no cross-resistance exists between pyronaridine
and chloroquine or between pyronaridine and quinoline
antimalarial drugs. The potency of pyronaridine against
chloroquine-resistant P. falciparum strains and those
with decreased susceptibility to quinine, monodesethyla-
modiaquine, or mefloquine, combined with the absence
of cross-resistance, suggests that pyronaridine and chlor-
oquine have different modes of action or that different
mechanisms of resistance are involved.
In addition, IC50 values for pyronaridine were unre-
lated to mutations in the transport protein genes pfcrt,
pfmdr1, pfmrp and pfnhe-1, which are involved in qui-
noline antimalarial drug resistance. These results are in
accordance with the absence of cross-resistance of
pyronaridine with quinolines. Qi et al suggested that
pyronaridine could be an inhibitor of P-glycoprotein-
mediated multidrug resistance in tumour cells [39,40].
However, this was not confirmed for Pgh1 or PfMRP.
Furthermore, because combinations of pyronaridine and
mefloquine, quinine, artesunate or dihydroartemisinin
have been shown to have antagonistic effects, this
hypothesis is of limited interest [19,30]. Susceptibilities
to these anti-malarial drugs are associated with poly-
morphisms in ABC transporters, such as Pgh1 and
PfMRP [41-45]. However the best association between
resistance to mefloquine and a molecular marker is
amplification of pfmdr1 gene in southest Asian isolates
and not polymorphisms in pfmdr1 [46].
A significant positive correlation was found between
responses to pyronaridine and artesunate (r
2 =0 . 1 9 ) .
Nevertheless, this coefficient of determination was lower
than those for chloroquine and monodesethylamodia-
quine, chloroquine and quinine and monodesethylamo-
diaquine and quinine. This coefficient of determination
was also lower than those obtained in previous studies
for dihydroartemisinin (0.31) [19] and artesunate (0.84)
[31]. A positive correlation between the IC50 values of
two anti-malarial drugs may suggest in vitro cross-resis-
tance or at least common mechanisms of action; how-
ever, the relationship between in vitro and in vivo
resistance depends on the level of resistance and the
coefficients of correlation (r) and determination (r
2). To
suggest the same mechanism of action or resistance
(which could induce cross-resistance) for two com-
pounds, the coefficient of determination must be high,
such as the one for chloroquine and monodesethylamo-
diaquine (r
2 = 0.84). A coefficient of determination of
0.19 means that only 19% of the variation in the
response to pyronaridine is explained by variation in the
response to artesunate. One explanation for this signifi-
cant positive correlation is that the range IC50 values for
the two drugs is extremely narrow, and most of the
strains are still susceptible to the both drugs. The one
possible exception is the strain IMT K4 from Cambodia
which shows IC50 values higher for pyronaridine (49
nM) and artesunate (4.0 nM). This strain was culture-
adapted in 1992 and there was no data on its in vivo
response to artemisinin derivatives (or longer clearance
time). In addition, in vitro test does not reflect artemisi-
nin derivatives failure or clinical response with longer
clearance time: IC50 values are not significantly different
between parasites from patients cured and parasites
from patient with treatment failure [14].
In this study, the excellent anti-malarial activities of
ACT components pyronaridine and artesunate were
confirmed, even against parasites resistant to chloro-
quine or pyrimethamine and with reduced susceptibility
to quinine, monodesethylamodiaquine or mefloquine.
A five-day regimen of pyronaridine alone (total dose =
1800 mg) produced a better cure rate than artesunate,
artemeter or mefloquine used alone in the same condi-
tions in Thailand [33]. The absence of cross-resistance
with quinoline drug and the fact that the IC50 values for
pyronaridine were found to be unrelated to mutations
in transport protein genes involved in quinoline antima-
larial drug resistance confirms the efficacy of the combi-
nation of pyronaridine and artesunate for areas in which
parasites are resistant to chloroquine or other quinoline
drugs [11].
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Additional file 1: Table S1: In vitro susceptibility of 23 strains of
Plasmodium falciparum to pyronaridine (PND) and pfcrt, pfmdr1,
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Additional file 2: Table S2: In vitro susceptibility of 23 strains of
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(IC50) to pyronaridine (PND), artesunate (AS), chloroquine (CQ),
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